Drug Profile
AG 519
Alternative Names: AG-519Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Agios Pharmaceuticals
- Class Antianaemics
- Mechanism of Action Pyruvate kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haemolytic anaemia
Most Recent Events
- 15 Dec 2016 Discontinued - Phase-I for Haemolytic anaemia (In volunteers) in United Kingdom (PO)
- 15 Dec 2016 Agios withdraws an IND application in USA for Haemolytic anaemia following a verbal notification of a clinical hold from the US Food and Drug Administration
- 04 Dec 2016 Pharmacodynamics and adverse events data from a phase I trial in Healthy volunteers presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)